The global demand for Veterinary Therapeutics Market is presumed to reach the valuation of nearly USD XX MN by 2028 from USD XX MN in 2021 with a CAGR of XX% during the period of 2022-2028.
Veterinary therapeutics refers to animal healthcare that involves prevention, treatment and easing symptoms of several diseases. This remedial science consists of drugs, vaccines, and medicated feed for the prevention and treatment of several pathological conditions in the animals. Both routes of drug administration, oral and parenteral are used in veterinary therapeutics.
Commercialization and R&D activities of new products act as a key driver for the veterinary therapeutics market. The substantial increase in the number of pet animals globally, growth and advancement in surgical and medical capabilities related to the animal treatment, rising focus on enhancing the overall wellness of animals, and significant progress in the development of new vaccines and medicines to curb the occurrence of new diseases are significant factors foreseen to influence the progress of the veterinary therapeutics market. However, evolving regulatory framework and trade, travel and market restrictions due to novel coronavirus pose serious challenges for the market participants. On the other hand, ease of administration (oral and parenteral), cost-effectiveness and appropriateness for mass vaccinations create favorable growth prospects. The market participants are anticipated to focus on the expansion of their product portfolio and surge investments in the development of DNA vaccines.
The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each application/product segment in the global market of veterinary therapeutics.
The entire veterinary therapeutics market has been sub-categorized into product type, animal type, route of administration and distribution channel. The report provides an analysis of these subsets with respect to the geographical segmentation. This research study will keep marketer informed and helps to identify the target demographics for a product or service.
By Product Type
By Animal Type
- Inactivated Vaccines
- Live Attenuated Vaccines
- Recombinant Vaccines
- Medicated Feed Additives
By Route of Administration
By Distribution Channel
- Companion Animals
- Livestock Animals
- Veterinary Hospitals
- Veterinary Clinics,
- Pharmacies & Drug Stores
This section covers regional segmentation which accentuates on current and future demand for veterinary therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Global Veterinary Therapeutics Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the veterinary therapeutics market include Zoetis, Inc., Merck Animal Health, Elanco Animal Health, Boehringer Ingelheim GmbH, Ceva Santé Animale, Virbac, Vetoquinol S.A., Dechra Pharmaceuticals PLC, Biovac, The Chanelle Group, ImmuCell Corporation. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
This market research report has been produced by gathering information on the basis of primary and secondary research. Secondary research has been done by using various sources which include (but not limited to) Company Websites, Paid Data Sources, Technical Journals, Financial Reports, SEC Filings, and other different industry publications.
If specific information is required which is not currently within the scope of the report, it can be provided as a part of customization.